Paracrine, Inc. is focused on harnessing the regenerative capabilities of the human body to develop innovative cell therapies aimed at treating serious chronic illnesses. Their primary technology involves a disease-modifying, first-in-class cell therapy that targets the underlying pathologies associated with conditions such as diabetic foot ulcers. The company is currently executing the ASCEND Clinical Trial, which is a Phase III FDA-approved study. Previous feasibility studies have shown promising results, with an impressive wound closure rate of 88% achieved through a single treatment, significantly outperforming standard care options. The therapy not only facilitates rapid healing but also demonstrates durability, with no recurrences reported in follow-up periods of up to 18 months.

Central to Paracrine's approach is the concept of paracrine signaling, which involves local cell-to-cell communication. Their adipose-derived regenerative cells (ADRCs) secrete a variety of signaling molecules, known as adipokines, that play crucial roles in regulating immune responses, inflammation, vascular function, and tissue repair. This pleiotropic mechanism allows Paracrine's therapies to address multiple aspects of complex conditions, including ischemia, inflammation, and tissue damage, thereby promoting effective and lasting healing outcomes. The company's commitment to advancing cell-based therapies positions it to potentially disrupt the wound care market, which is valued at $21 billion.

United States

Paracrine is a San Diego-based company in late-stage clinical development  of an Immuno-NeuroVascular Regenerative Therapy - a multi-dimensional biologic therapy for complex diseases. Our primary focus is an FDA approved Phase III Trial in chronic diabetic foot ulcers where feasibility data from four prior studies demonstrated twice the healing rate in less than half the time and no recurrence out to 18 monhts.

Paracrine

Company Details